$AGIO
Agios Pharmaceuticals Inc

2022 Q1 Form 10-Q Financial Statement

#000143922222000040 Filed on May 05, 2022

View on sec.gov

Income Statement

Concept 2022 Q1 2021 Q4 2021 Q1
Revenue $832.0K $0.00 $0.00
YoY Change -100.0% -100.0%
Cost Of Revenue $339.0K $0.00
YoY Change -100.0%
Gross Profit $493.0K $0.00
YoY Change -100.0%
Gross Profit Margin 59.25%
Selling, General & Admin $31.52M $31.53M $33.55M
YoY Change -6.07% -20.74% 5.94%
% of Gross Profit 6392.49%
Research & Development $70.12M $73.30M $57.67M
YoY Change 21.6% -23.44% 4.17%
% of Gross Profit 14223.73%
Depreciation & Amortization $2.478M $2.202M $2.500M
YoY Change -0.88% -18.44% 1.05%
% of Gross Profit 502.64%
Operating Expenses $70.12M $104.8M $57.67M
YoY Change 21.6% -22.65% 4.17%
Operating Profit -$101.1M -$91.22M
YoY Change 10.88% 4.81%
Interest Expense $694.0K $332.0K $340.0K
YoY Change 104.12% -57.97% -88.44%
% of Operating Profit
Other Income/Expense, Net $2.973M $3.268M
YoY Change -154.38%
Pretax Income -$94.77M -$98.58M -$90.88M
YoY Change 4.29% 16.61% 8.07%
Income Tax $0.00 $0.00
% Of Pretax Income
Net Earnings -$94.77M -$94.63M $1.874B
YoY Change -105.06% -3.11% -4756.01%
Net Earnings / Revenue -11391.11%
Basic Earnings Per Share -$1.74 -$1.74 $26.95
Diluted Earnings Per Share -$1.74 -$1.74 $26.95
COMMON SHARES
Basic Shares Outstanding 54.56M shares 54.31M shares 69.54M shares
Diluted Shares Outstanding 54.56M shares 69.54M shares

Balance Sheet

Concept 2022 Q1 2021 Q4 2021 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $923.5M $1.020B $2.336B
YoY Change -60.46% 78.04% 341.83%
Cash & Equivalents $80.03M $203.1M $1.888B
Short-Term Investments $843.5M $816.9M $447.6M
Other Short-Term Assets $43.23M $39.84M $19.50M
YoY Change 121.67% 68.08% -33.22%
Inventory $2.485M $0.00
Prepaid Expenses
Receivables $540.0K
Other Receivables $5.365M $4.378M
Total Short-Term Assets $975.1M $1.064B $2.355B
YoY Change -58.59% 67.15% 301.02%
LONG-TERM ASSETS
Property, Plant & Equipment $29.20M $28.92M $28.98M
YoY Change 0.76% -6.14% -14.37%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments $255.8M $266.4M $21.60M
YoY Change 1084.43% 172.93% -74.44%
Other Assets $2.900M $2.900M $0.00
YoY Change -100.0%
Total Long-Term Assets $360.7M $373.5M $133.3M
YoY Change 170.56% 72.7% -37.25%
TOTAL ASSETS
Total Short-Term Assets $975.1M $1.064B $2.355B
Total Long-Term Assets $360.7M $373.5M $133.3M
Total Assets $1.336B $1.438B $2.488B
YoY Change -46.32% 68.56% 211.16%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $11.55M $16.70M $51.22M
YoY Change -77.45% -5.78% 173.82%
Accrued Expenses $19.75M $31.97M $23.60M
YoY Change -16.33% 3.79% -40.45%
Deferred Revenue $2.500M $0.00
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $250.0K $331.0K $300.0K
YoY Change -16.67% 10.33% 0.0%
Total Short-Term Liabilities $45.79M $59.83M $96.50M
YoY Change -52.55% -36.62% 38.14%
LONG-TERM LIABILITIES
Long-Term Debt $276.0K $276.0K $200.0K
YoY Change 38.0% -8.0% -66.67%
Other Long-Term Liabilities $82.34M $276.0K $95.10M
YoY Change -13.42% -99.92% -8.56%
Total Long-Term Liabilities $82.61M $276.0K $95.30M
YoY Change -13.31% -99.92% -8.89%
TOTAL LIABILITIES
Total Short-Term Liabilities $45.79M $59.83M $96.50M
Total Long-Term Liabilities $82.61M $276.0K $95.30M
Total Liabilities $128.4M $145.8M $191.8M
YoY Change -33.05% -67.86% 9.95%
SHAREHOLDERS EQUITY
Retained Earnings -$333.5M -$238.8M $30.85M
YoY Change -1181.15% -87.05% -101.98%
Common Stock $2.351B $2.334B $2.266B
YoY Change 3.77% 4.08% 3.86%
Preferred Stock
YoY Change
Treasury Stock (at cost) $802.5M $802.5M
YoY Change
Treasury Stock Shares 16.22M shares 16.22M shares
Shareholders Equity $1.207B $1.292B $2.297B
YoY Change
Total Liabilities & Shareholders Equity $1.336B $1.438B $2.488B
YoY Change -46.32% 68.56% 211.16%

Cashflow Statement

Concept 2022 Q1 2021 Q4 2021 Q1
OPERATING ACTIVITIES
Net Income -$94.77M -$94.63M $1.874B
YoY Change -105.06% -3.11% -4756.01%
Depreciation, Depletion And Amortization $2.478M $2.202M $2.500M
YoY Change -0.88% -18.44% 1.05%
Cash From Operating Activities -$97.74M -$84.09M -$120.7M
YoY Change -19.06% 70.23% 14.61%
INVESTING ACTIVITIES
Capital Expenditures $2.804M -$4.502M $1.012M
YoY Change 177.08% 350.2% -75.88%
Acquisitions
YoY Change
Other Investing Activities -$23.77M -$89.92M $1.875B
YoY Change -101.27% -224.02% 1565.28%
Cash From Investing Activities -$26.57M -$94.42M $1.874B
YoY Change -101.42% -232.42% 1633.09%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities $1.208M -18.59M $7.261M
YoY Change -83.36% -3197.67% 34.84%
NET CHANGE
Cash From Operating Activities -$97.74M -84.09M -$120.7M
Cash From Investing Activities -$26.57M -94.42M $1.874B
Cash From Financing Activities $1.208M -18.59M $7.261M
Net Change In Cash -$123.1M -197.1M $1.761B
YoY Change -106.99% -975.99% 21470.56%
FREE CASH FLOW
Cash From Operating Activities -$97.74M -$84.09M -$120.7M
Capital Expenditures $2.804M -$4.502M $1.012M
Free Cash Flow -$100.5M -$79.59M -$121.8M
YoY Change -17.43% 64.44% 11.14%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2022Q1 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2022
CY2022Q1 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2022Q1 dei Amendment Flag
AmendmentFlag
false
CY2022Q1 dei Entity Central Index Key
EntityCentralIndexKey
0001439222
CY2022Q1 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2022Q1 dei Document Type
DocumentType
10-Q
CY2022Q1 dei Document Quarterly Report
DocumentQuarterlyReport
true
CY2022Q1 dei Document Period End Date
DocumentPeriodEndDate
2022-03-31
CY2022Q1 dei Document Transition Report
DocumentTransitionReport
false
CY2022Q1 dei Entity File Number
EntityFileNumber
001-36014
CY2022Q1 dei Entity Registrant Name
EntityRegistrantName
AGIOS PHARMACEUTICALS, INC.
CY2022Q1 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2022Q1 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
26-0662915
CY2022Q1 dei Entity Address Address Line1
EntityAddressAddressLine1
88 Sidney Street
CY2022Q1 dei Entity Address City Or Town
EntityAddressCityOrTown
Cambridge
CY2022Q1 dei Entity Address State Or Province
EntityAddressStateOrProvince
MA
CY2022Q1 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
02139
CY2022Q1 dei City Area Code
CityAreaCode
617
CY2022Q1 dei Local Phone Number
LocalPhoneNumber
649-8600
CY2022Q1 dei Security12b Title
Security12bTitle
Common Stock, Par Value $0.001 per share
CY2022Q1 dei Trading Symbol
TradingSymbol
AGIO
CY2022Q1 dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2022Q1 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2022Q1 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2022Q1 dei Entity Filer Category
EntityFilerCategory
Large Accelerated Filer
CY2022Q1 dei Entity Small Business
EntitySmallBusiness
false
CY2022Q1 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
CY2022Q1 dei Entity Shell Company
EntityShellCompany
false
CY2022Q2 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
54788927 shares
CY2022Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
80026000 USD
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
203126000 USD
CY2022Q1 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
843503000 USD
CY2021Q4 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
816892000 USD
CY2022Q1 us-gaap Contract With Customer Asset Net Current
ContractWithCustomerAssetNetCurrent
540000 USD
CY2021Q4 us-gaap Contract With Customer Asset Net Current
ContractWithCustomerAssetNetCurrent
0 USD
CY2022Q1 us-gaap Other Receivables Net Current
OtherReceivablesNetCurrent
5365000 USD
CY2021Q4 us-gaap Other Receivables Net Current
OtherReceivablesNetCurrent
4378000 USD
CY2022Q1 us-gaap Inventory Net
InventoryNet
2485000 USD
CY2021Q4 us-gaap Inventory Net
InventoryNet
0 USD
CY2022Q1 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
43226000 USD
CY2021Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
39835000 USD
CY2022Q1 us-gaap Assets Current
AssetsCurrent
975145000 USD
CY2021Q4 us-gaap Assets Current
AssetsCurrent
1064231000 USD
CY2022Q1 us-gaap Available For Sale Securities Debt Securities Noncurrent
AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
255836000 USD
CY2021Q4 us-gaap Available For Sale Securities Debt Securities Noncurrent
AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
266375000 USD
CY2022Q1 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
72688000 USD
CY2021Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
75124000 USD
CY2022Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
29195000 USD
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
28923000 USD
CY2022Q1 us-gaap Finance Lease Right Of Use Asset
FinanceLeaseRightOfUseAsset
95000 USD
CY2021Q4 us-gaap Finance Lease Right Of Use Asset
FinanceLeaseRightOfUseAsset
183000 USD
CY2022Q1 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
2900000 USD
CY2021Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
2900000 USD
CY2022Q1 us-gaap Assets
Assets
1335859000 USD
CY2021Q4 us-gaap Assets
Assets
1437736000 USD
CY2022Q1 us-gaap Accounts Payable Current
AccountsPayableCurrent
11551000 USD
CY2021Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
16700000 USD
CY2022Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
19747000 USD
CY2021Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
31967000 USD
CY2022Q1 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
11744000 USD
CY2021Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
10828000 USD
CY2022Q1 us-gaap Finance Lease Liability Current
FinanceLeaseLiabilityCurrent
250000 USD
CY2021Q4 us-gaap Finance Lease Liability Current
FinanceLeaseLiabilityCurrent
331000 USD
CY2022Q1 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
2500000 USD
CY2021Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
0 USD
CY2022Q1 us-gaap Liabilities Current
LiabilitiesCurrent
45792000 USD
CY2021Q4 us-gaap Liabilities Current
LiabilitiesCurrent
59826000 USD
CY2022Q1 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
82338000 USD
CY2021Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
85659000 USD
CY2022Q1 us-gaap Finance Lease Liability Noncurrent
FinanceLeaseLiabilityNoncurrent
276000 USD
CY2021Q4 us-gaap Finance Lease Liability Noncurrent
FinanceLeaseLiabilityNoncurrent
276000 USD
CY2022Q1 us-gaap Liabilities
Liabilities
128406000 USD
CY2021Q4 us-gaap Liabilities
Liabilities
145761000 USD
CY2022Q1 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2021Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2022Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
25000000 shares
CY2021Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
25000000 shares
CY2022Q1 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2021Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2022Q1 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2021Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2022Q1 us-gaap Preferred Stock Value
PreferredStockValue
0 USD
CY2021Q4 us-gaap Preferred Stock Value
PreferredStockValue
0 USD
CY2021Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2022Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2021Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
125000000 shares
CY2022Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
125000000 shares
CY2022Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
70993277 shares
CY2022Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
54776467 shares
CY2021Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
70550631 shares
CY2021Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
54334220 shares
CY2022Q1 us-gaap Common Stock Value
CommonStockValue
71000 USD
CY2021Q4 us-gaap Common Stock Value
CommonStockValue
71000 USD
CY2022Q1 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
2351147000 USD
CY2021Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
2334348000 USD
CY2022Q1 us-gaap Accumulated Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
-7745000 USD
CY2021Q4 us-gaap Accumulated Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
-1198000 USD
CY2022Q1 us-gaap Treasury Stock Shares
TreasuryStockShares
16216411 shares
CY2021Q4 us-gaap Treasury Stock Shares
TreasuryStockShares
16216411 shares
CY2022Q1 us-gaap Treasury Stock Value
TreasuryStockValue
802486000 USD
CY2021Q4 us-gaap Treasury Stock Value
TreasuryStockValue
802486000 USD
CY2022Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-333534000 USD
CY2021Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-238760000 USD
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
1207453000 USD
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
1291975000 USD
CY2022Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
1335859000 USD
CY2021Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
1437736000 USD
CY2022Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
832000 USD
CY2021Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
0 USD
CY2022Q1 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
339000 USD
CY2021Q1 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
0 USD
CY2022Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
70123000 USD
CY2021Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
57667000 USD
CY2022Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
31515000 USD
CY2021Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
33550000 USD
CY2022Q1 us-gaap Costs And Expenses
CostsAndExpenses
101977000 USD
CY2021Q1 us-gaap Costs And Expenses
CostsAndExpenses
91217000 USD
CY2022Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-101145000 USD
CY2021Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-91217000 USD
CY2022Q1 us-gaap Gain Loss On Sale Of Business
GainLossOnSaleOfBusiness
2704000 USD
CY2021Q1 us-gaap Gain Loss On Sale Of Business
GainLossOnSaleOfBusiness
0 USD
CY2022Q1 us-gaap Investment Income Interest
InvestmentIncomeInterest
694000 USD
CY2021Q1 us-gaap Investment Income Interest
InvestmentIncomeInterest
340000 USD
CY2022Q1 us-gaap Other Operating Income Expense Net
OtherOperatingIncomeExpenseNet
2973000 USD
CY2021Q1 us-gaap Other Operating Income Expense Net
OtherOperatingIncomeExpenseNet
0 USD
CY2022Q1 us-gaap Income Loss From Continuing Operations
IncomeLossFromContinuingOperations
-94774000 USD
CY2021Q1 us-gaap Income Loss From Continuing Operations
IncomeLossFromContinuingOperations
-90877000 USD
CY2022Q1 us-gaap Income Loss From Discontinued Operations Net Of Tax Attributable To Reporting Entity
IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity
0 USD
CY2021Q1 us-gaap Income Loss From Discontinued Operations Net Of Tax Attributable To Reporting Entity
IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity
1965202000 USD
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-94774000 USD
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
1874325000 USD
CY2022Q1 us-gaap Income Loss From Continuing Operations Per Basic Share
IncomeLossFromContinuingOperationsPerBasicShare
-1.74
CY2022Q1 us-gaap Income Loss From Continuing Operations Per Diluted Share
IncomeLossFromContinuingOperationsPerDilutedShare
-1.74
CY2021Q1 us-gaap Income Loss From Continuing Operations Per Basic Share
IncomeLossFromContinuingOperationsPerBasicShare
-1.31
CY2021Q1 us-gaap Income Loss From Continuing Operations Per Diluted Share
IncomeLossFromContinuingOperationsPerDilutedShare
-1.31
CY2022Q1 us-gaap Income Loss From Discontinued Operations Net Of Tax Per Basic Share
IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare
0
CY2022Q1 us-gaap Income Loss From Discontinued Operations Net Of Tax Per Diluted Share
IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare
0
CY2021Q1 us-gaap Income Loss From Discontinued Operations Net Of Tax Per Diluted Share
IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare
28.26
CY2021Q1 us-gaap Income Loss From Discontinued Operations Net Of Tax Per Basic Share
IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare
28.26
CY2022Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.74
CY2022Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.74
CY2021Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
26.95
CY2021Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
26.95
CY2022Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
54555467 shares
CY2022Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
54555467 shares
CY2021Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
69543510 shares
CY2021Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
69543510 shares
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-94774000 USD
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
1874325000 USD
CY2022Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-6547000 USD
CY2021Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-108000 USD
CY2022Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-101321000 USD
CY2021Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
1874217000 USD
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
1291975000 USD
CY2022Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
1289000 USD
CY2022Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
15510000 USD
CY2022Q1 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-6547000 USD
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-94774000 USD
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
1207453000 USD
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
399500000 USD
CY2021Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
7347000 USD
CY2021Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
14854000 USD
CY2021Q1 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-108000 USD
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
1874325000 USD
CY2021Q1 agio Stockholders Equity Disposition Of Business
StockholdersEquityDispositionOfBusiness
-712000 USD
CY2021Q1 us-gaap Stockholders Equity
StockholdersEquity
2296630000 USD
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-94774000 USD
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
1874325000 USD
CY2022Q1 us-gaap Income Loss From Discontinued Operations Net Of Tax Attributable To Reporting Entity
IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity
0 USD
CY2021Q1 us-gaap Income Loss From Discontinued Operations Net Of Tax Attributable To Reporting Entity
IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity
1965202000 USD
CY2022Q1 us-gaap Income Loss From Continuing Operations
IncomeLossFromContinuingOperations
-94774000 USD
CY2021Q1 us-gaap Income Loss From Continuing Operations
IncomeLossFromContinuingOperations
-90877000 USD
CY2022Q1 us-gaap Other Depreciation And Amortization
OtherDepreciationAndAmortization
2478000 USD
CY2021Q1 us-gaap Other Depreciation And Amortization
OtherDepreciationAndAmortization
2479000 USD
CY2022Q1 us-gaap Share Based Compensation
ShareBasedCompensation
15510000 USD
CY2021Q1 us-gaap Share Based Compensation
ShareBasedCompensation
14854000 USD
CY2022Q1 us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
-1150000 USD
CY2021Q1 us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
-1664000 USD
CY2022Q1 us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
2436000 USD
CY2021Q1 us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
2417000 USD
CY2022Q1 us-gaap Increase Decrease In Contract With Customer Asset
IncreaseDecreaseInContractWithCustomerAsset
540000 USD
CY2021Q1 us-gaap Increase Decrease In Contract With Customer Asset
IncreaseDecreaseInContractWithCustomerAsset
0 USD
CY2022Q1 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
2485000 USD
CY2021Q1 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
0 USD
CY2022Q1 us-gaap Increase Decrease In Other Receivables
IncreaseDecreaseInOtherReceivables
987000 USD
CY2021Q1 us-gaap Increase Decrease In Other Receivables
IncreaseDecreaseInOtherReceivables
0 USD
CY2022Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
3391000 USD
CY2021Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
3621000 USD
CY2022Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-5007000 USD
CY2021Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-2941000 USD
CY2022Q1 us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
-12220000 USD
CY2021Q1 us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
-12697000 USD
CY2022Q1 us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
2500000 USD
CY2021Q1 us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
0 USD
CY2022Q1 us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-2405000 USD
CY2021Q1 us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-1504000 USD
CY2022Q1 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-97735000 USD
CY2021Q1 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-90226000 USD
CY2022Q1 us-gaap Cash Provided By Used In Operating Activities Discontinued Operations
CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations
0 USD
CY2021Q1 us-gaap Cash Provided By Used In Operating Activities Discontinued Operations
CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations
-30523000 USD
CY2022Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-97735000 USD
CY2021Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-120749000 USD
CY2022Q1 us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
355916000 USD
CY2021Q1 us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
61863000 USD
CY2022Q1 us-gaap Proceeds From Sale And Maturity Of Available For Sale Securities
ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
332147000 USD
CY2021Q1 us-gaap Proceeds From Sale And Maturity Of Available For Sale Securities
ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
134016000 USD
CY2022Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
2804000 USD
CY2021Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
1012000 USD
CY2022Q1 us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-26573000 USD
CY2021Q1 us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
71141000 USD
CY2022Q1 us-gaap Cash Provided By Used In Investing Activities Discontinued Operations
CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations
0 USD
CY2021Q1 us-gaap Cash Provided By Used In Investing Activities Discontinued Operations
CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations
1802936000 USD
CY2022Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-26573000 USD
CY2021Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
1874077000 USD
CY2022Q1 us-gaap Finance Lease Principal Payments
FinanceLeasePrincipalPayments
81000 USD
CY2021Q1 us-gaap Finance Lease Principal Payments
FinanceLeasePrincipalPayments
86000 USD
CY2022Q1 us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
1289000 USD
CY2021Q1 us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
7347000 USD
CY2022Q1 us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
1208000 USD
CY2021Q1 us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
7261000 USD
CY2022Q1 us-gaap Cash Provided By Used In Financing Activities Discontinued Operations
CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations
0 USD
CY2021Q1 us-gaap Cash Provided By Used In Financing Activities Discontinued Operations
CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations
0 USD
CY2022Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
1208000 USD
CY2021Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
7261000 USD
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-123100000 USD
CY2021Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
1760589000 USD
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
203126000 USD
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
127436000 USD
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
80026000 USD
CY2021Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
1888025000 USD
CY2022Q1 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
1536000 USD
CY2021Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
4000 USD
CY2021Q1 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
6000 USD
CY2022Q1 us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
1842000 USD
CY2021Q1 us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
0 USD
CY2022Q1 us-gaap Prior Period Reclassification Adjustment Description
PriorPeriodReclassificationAdjustmentDescription
<div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Reclassifications</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain amounts in prior periods have been reclassified to reflect the impact of the discontinued operations treatment of the oncology business in order to conform to the current period presentation.</span></div>
CY2022Q1 us-gaap Use Of Estimates
UseOfEstimates
<div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of estimates</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of our condensed consolidated financial statements requires us to make estimates, judgments and assumptions that may affect the reported amounts of assets, liabilities, equity, revenues and expenses and related disclosure of contingent assets and liabilities. On an ongoing basis we evaluate our estimates, judgments and methodologies. We base our estimates on historical experience and on various other assumptions that we believe are reasonable, the results of which form the basis for making judgments about the carrying values of assets, liabilities and equity and the amount of revenues and expenses. The full extent to which the COVID-19 pandemic will directly or indirectly impact our business, results of operations and financial condition, including expenses, reserves and allowances, clinical trials, research and development costs and employee-related amounts, will depend on future developments that are highly uncertain, including as a result of new information that may emerge concerning COVID-19 and any variant strains of the virus and the actions taken to contain the pandemic or treat COVID-19, as well as the economic impact on local, regional, national and international customers and markets. We have made estimates of the impact of COVID-19 within our financial statements and there may be changes to those estimates in future periods. Actual results may differ from these estimates.</span></div>
CY2022Q1 us-gaap Stock Repurchase Program Authorized Amount1
StockRepurchaseProgramAuthorizedAmount1
1200000000 USD
CY2022Q1 us-gaap Cash Cash Equivalents And Short Term Investments
CashCashEquivalentsAndShortTermInvestments
1200000000 USD
CY2022Q1 us-gaap Marketable Securities Realized Gain Loss
MarketableSecuritiesRealizedGainLoss
0 USD
CY2021Q1 us-gaap Marketable Securities Realized Gain Loss
MarketableSecuritiesRealizedGainLoss
0 USD
CY2022Q1 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
1107084000 USD
CY2022Q1 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
15000 USD
CY2022Q1 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
7760000 USD
CY2022Q1 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
1099339000 USD
CY2021Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
1084465000 USD
CY2022Q1 us-gaap Inventory Work In Process Net Of Reserves
InventoryWorkInProcessNetOfReserves
2185000 USD
CY2021Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
1202000 USD
CY2021Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
1083267000 USD
CY2022Q1 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months Number Of Positions
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions
307 security
CY2021Q4 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months Number Of Positions
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions
294 security
CY2022Q1 us-gaap Debt Securities Available For Sale Allowance For Credit Loss
DebtSecuritiesAvailableForSaleAllowanceForCreditLoss
0 USD
CY2021Q4 us-gaap Debt Securities Available For Sale Allowance For Credit Loss
DebtSecuritiesAvailableForSaleAllowanceForCreditLoss
0 USD
CY2022Q1 us-gaap Debt Securities Available For Sale Unrealized Loss Position
DebtSecuritiesAvailableForSaleUnrealizedLossPosition
1066800000 USD
CY2021Q4 us-gaap Debt Securities Available For Sale Unrealized Loss Position
DebtSecuritiesAvailableForSaleUnrealizedLossPosition
950500000 USD
CY2022Q1 us-gaap Debt Securities Available For Sale Unrealized Loss Position Number Of Positions
DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions
0 security
CY2021Q4 us-gaap Debt Securities Available For Sale Unrealized Loss Position Number Of Positions
DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions
0 security
CY2022Q1 us-gaap Inventory Raw Materials Net Of Reserves
InventoryRawMaterialsNetOfReserves
0 USD
CY2021Q4 us-gaap Inventory Raw Materials Net Of Reserves
InventoryRawMaterialsNetOfReserves
0 USD
CY2021Q4 us-gaap Inventory Work In Process Net Of Reserves
InventoryWorkInProcessNetOfReserves
0 USD
CY2022Q1 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
300000 USD
CY2021Q4 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
0 USD
CY2022Q1 us-gaap Inventory Net
InventoryNet
2485000 USD
CY2021Q4 us-gaap Inventory Net
InventoryNet
0 USD
CY2022Q1 us-gaap Lessee Operating Lease Remaining Lease Term
LesseeOperatingLeaseRemainingLeaseTerm
P6Y
CY2022Q1 us-gaap Operating Lease Cost
OperatingLeaseCost
3800000 USD
CY2021Q1 us-gaap Operating Lease Cost
OperatingLeaseCost
3800000 USD
CY2022Q1 us-gaap Operating Lease Payments
OperatingLeasePayments
3800000 USD
CY2021Q1 us-gaap Operating Lease Payments
OperatingLeasePayments
3600000 USD
CY2022Q1 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.057
CY2021Q4 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.057
CY2022Q1 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P5Y10M24D
CY2022Q1 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
1952000 USD
CY2021Q4 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P6Y2M12D
CY2022Q1 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
11784000 USD
CY2022Q1 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
18126000 USD
CY2022Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
18660000 USD
CY2022Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
19507000 USD
CY2022Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
20151000 USD
CY2022Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Five
LesseeOperatingLeaseLiabilityPaymentsDueYearFive
20755000 USD
CY2022Q1 us-gaap Lessee Operating Lease Liability Payments Due After Year Five
LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive
3479000 USD
CY2022Q1 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
112462000 USD
CY2022Q1 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
18380000 USD
CY2022Q1 us-gaap Operating Lease Liability
OperatingLeaseLiability
94082000 USD
CY2022Q1 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
2900000 USD
CY2021Q3 agio Lessee Operating Sublease Area Of Premises Subleased
LesseeOperatingSubleaseAreaOfPremisesSubleased
13000 sqft
CY2022Q1 us-gaap Sublease Income
SubleaseIncome
400000 USD
CY2022Q1 us-gaap Lessor Operating Lease Payments To Be Received Remainder Of Fiscal Year
LessorOperatingLeasePaymentsToBeReceivedRemainderOfFiscalYear
842000 USD
CY2022Q1 us-gaap Lessor Operating Lease Payments To Be Received Next Twelve Months
LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths
1152000 USD
CY2022Q1 us-gaap Lessor Operating Lease Payments To Be Received Two Years
LessorOperatingLeasePaymentsToBeReceivedTwoYears
1186000 USD
CY2022Q1 us-gaap Lessor Operating Lease Payments To Be Received
LessorOperatingLeasePaymentsToBeReceived
3180000 USD
CY2022Q1 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
5387000 USD
CY2021Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
19818000 USD
CY2022Q1 agio Accrued Research And Development Costs Current
AccruedResearchAndDevelopmentCostsCurrent
8626000 USD
CY2021Q4 agio Accrued Research And Development Costs Current
AccruedResearchAndDevelopmentCostsCurrent
5980000 USD
CY2021Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
2335000 USD
CY2022Q1 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
3782000 USD
CY2021Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
3834000 USD
CY2022Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
19747000 USD
CY2021Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
31967000 USD
CY2021Q4 agio Contract With Customer Contractual Adjustment Reserve
ContractWithCustomerContractualAdjustmentReserve
0 USD
CY2021Q4 agio Contract With Customer Rebate Reserve
ContractWithCustomerRebateReserve
0 USD
CY2021Q4 agio Contract With Customer Right To Recover Product Reserve
ContractWithCustomerRightToRecoverProductReserve
0 USD
CY2021Q4 agio Contract With Customer Total Allowances And Reserves
ContractWithCustomerTotalAllowancesAndReserves
0 USD
CY2022Q1 agio Current Year Provision For Contractual Adjustments
CurrentYearProvisionForContractualAdjustments
37000 USD
CY2022Q1 agio Current Year Provisions For Rebate Reserve
CurrentYearProvisionsForRebateReserve
56000 USD
CY2022Q1 agio Provision For Right To Recover Product In Current Year
ProvisionForRightToRecoverProductInCurrentYear
9000 USD
CY2022Q1 agio Contract With Customer Current Year Reserve Provisions
ContractWithCustomerCurrentYearReserveProvisions
102000 USD
CY2022Q1 agio Prior Year Provision For Contractual Adjustments
PriorYearProvisionForContractualAdjustments
0 USD
CY2022Q1 agio Prior Year Provisions For Rebate Reserve
PriorYearProvisionsForRebateReserve
0 USD
CY2022Q1 agio Provision For Right To Recover Product In Prior Years
ProvisionForRightToRecoverProductInPriorYears
0 USD
CY2022Q1 agio Contract With Customer Prior Years Reserve Provisions
ContractWithCustomerPriorYearsReserveProvisions
0 USD
CY2022Q1 agio Contract With Customer Contract Adjustment Recoveries Current Year
ContractWithCustomerContractAdjustmentRecoveriesCurrentYear
11000 USD
CY2022Q1 agio Contract With Customer Rebate Reserve Recoveries In Current Year
ContractWithCustomerRebateReserveRecoveriesInCurrentYear
0 USD
CY2022Q1 agio Contract With Customer Right To Recover Product Current Year Recoveries
ContractWithCustomerRightToRecoverProductCurrentYearRecoveries
0 USD
CY2022Q1 agio Contract With Customer Current Year Reserve Recoveries
ContractWithCustomerCurrentYearReserveRecoveries
11000 USD
CY2022Q1 agio Contract With Customer Contract Adjustment Recoveries Prior Year
ContractWithCustomerContractAdjustmentRecoveriesPriorYear
0 USD
CY2022Q1 agio Contract With Customer Rebate Reserve Recoveries In Prior Years
ContractWithCustomerRebateReserveRecoveriesInPriorYears
0 USD
CY2022Q1 agio Contract With Customer Right To Recover Product Prior Year Recoveries
ContractWithCustomerRightToRecoverProductPriorYearRecoveries
0 USD
CY2022Q1 agio Contract With Customer Prior Years Reserve Recoveries
ContractWithCustomerPriorYearsReserveRecoveries
0 USD
CY2022Q1 agio Contract With Customer Contractual Adjustment Reserve
ContractWithCustomerContractualAdjustmentReserve
26000 USD
CY2022Q1 agio Contract With Customer Rebate Reserve
ContractWithCustomerRebateReserve
56000 USD
CY2022Q1 agio Contract With Customer Right To Recover Product Reserve
ContractWithCustomerRightToRecoverProductReserve
9000 USD
CY2022Q1 agio Contract With Customer Total Allowances And Reserves
ContractWithCustomerTotalAllowancesAndReserves
91000 USD
CY2022Q1 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
17000 USD
CY2021Q4 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
0 USD
CY2022Q1 agio Contract With Customer Allowance And Reserves Liability
ContractWithCustomerAllowanceAndReservesLiability
74000 USD
CY2021Q4 agio Contract With Customer Allowance And Reserves Liability
ContractWithCustomerAllowanceAndReservesLiability
0 USD
CY2022Q1 agio Contract With Customer Total Allowances And Reserves
ContractWithCustomerTotalAllowancesAndReserves
91000 USD
CY2021Q4 agio Contract With Customer Total Allowances And Reserves
ContractWithCustomerTotalAllowancesAndReserves
0 USD
CY2021Q4 us-gaap Contract With Customer Asset Net
ContractWithCustomerAssetNet
0 USD
CY2022Q1 agio Contract With Customer Asset Revenue Recognized
ContractWithCustomerAssetRevenueRecognized
934000 USD
CY2022Q1 agio Contract With Customer Asset Proceeds From Collection Of Receivables
ContractWithCustomerAssetProceedsFromCollectionOfReceivables
394000 USD
CY2022Q1 us-gaap Contract With Customer Asset Net
ContractWithCustomerAssetNet
540000 USD
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
4798826 shares
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
58.51
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
647713 shares
CY2022Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
32.23
CY2022Q1 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
3250 shares
CY2022Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
4.92
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
168145 shares
CY2022Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
68.62
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
5275144 shares
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
55.02
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
3494909 shares
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
59.81
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
5275144 shares
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
55.02
CY2022Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
15510000 USD
CY2021Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
14854000 USD
CY2022Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
15510000 USD
CY2021Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
14854000 USD
CY2022Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
6571153 shares
CY2021Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
7452431 shares
CY2022Q1 us-gaap Discontinued Operation Tax Effect Of Discontinued Operation
DiscontinuedOperationTaxEffectOfDiscontinuedOperation
0 USD
CY2021Q1 us-gaap Discontinued Operation Tax Effect Of Discontinued Operation
DiscontinuedOperationTaxEffectOfDiscontinuedOperation
12900000 USD
CY2021Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 USD
CY2022Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 USD

Files In Submission

Name View Source Status
0001439222-22-000040-index-headers.html Edgar Link pending
0001439222-22-000040-index.html Edgar Link pending
0001439222-22-000040.txt Edgar Link pending
0001439222-22-000040-xbrl.zip Edgar Link pending
agio-20220331.htm Edgar Link pending
agio-20220331.xsd Edgar Link pending
agio-20220331_cal.xml Edgar Link unprocessable
agio-20220331_def.xml Edgar Link unprocessable
agio-20220331_htm.xml Edgar Link completed
agio-20220331_lab.xml Edgar Link unprocessable
agio-20220331_pre.xml Edgar Link unprocessable
exhibit31-1x03x31x22.htm Edgar Link pending
exhibit31-2x03x31x22.htm Edgar Link pending
exhibit32-1x03x31x22.htm Edgar Link pending
exhibit32-2x03x31x22.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending